Provided by Tiger Fintech (Singapore) Pte. Ltd.

Belite Bio, Inc.

56.40
-0.8800-1.54%
Post-market: 56.400.00000.00%18:23 EDT
Volume:20.44K
Turnover:1.16M
Market Cap:1.80B
PE:-47.65
High:58.01
Open:56.76
Low:55.51
Close:57.28
Loading ...

Company Profile

Company Name:
Belite Bio, Inc.
Exchange:
NASDAQ
Establishment Date:
2016
Employees:
25
Office Location:
12750 High Bluff Drive,Suite 475,San Diego,California,United States
Zip Code:
92130
Fax:
- -
Introduction:
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Directors

Name
Position
Yu Hsin Lin
Chief Executive Officer, Chairman of the Board
Gary C. Biddle
Independent Director
Hao Yuan Chuang
Chief Financial Officer, Director
Ita Lu
Independent Director
John M. Longo
Independent Director
Hung Wei Chen
Director
Wan Shan Chen
Director

Shareholders

Name
Position
Yu Hsin Lin
Chief Executive Officer, Chairman of the Board
Hao Yuan Chuang
Chief Financial Officer, Director
Ching Chen Chiu
Vice President of Clinical Operations
Nathan L. Mata
Chief Scientific Officer